Literature DB >> 11782822

Serial electrocardiographic changes as a predictor of cardiovascular toxicity in acute tricyclic antidepressant overdose.

Narpinder Singh1, Harinder K Singh, Ijaz A Khan.   

Abstract

Tricyclic antidepressant agents continue to be a leading cause of significant morbidity and mortality in reported poisonings involving pharmaceutical agents. Although the history and physical examination play an important role in the assessment of patients with tricyclic antidepressant overdose, the presence of anticholinergic features on examination cannot predict the severity of the overdose. Several clinical variables, in particular electrocardiographic (ECG) changes, have been proposed as a guide to determine the severity of the tricyclic antidepressant poisoning. The authors describe a patient with tricyclic antidepressant overdose who presented with altered mental status and whose serial ECG changes played a significant role in diagnosing and predicting the impending cardiovascular toxicity. The role of ECG changes in making the diagnosis and assessing the severity of the tricyclic antidepressant overdose is reviewed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782822     DOI: 10.1097/00045391-200201000-00012

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

Review 1.  Clinical utility of aVR-The neglected electrocardiographic lead.

Authors:  Dmitriy Kireyev; Mikhail V Arkhipov; Stephen T Zador; Joseph A Paris; William E Boden
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 2.  Fab antibody fragments: some applications in clinical toxicology.

Authors:  Robert J Flanagan; Alison L Jones
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Comment on "Serial monitoring of lead aVR in patients with prolonged unconsciousness following tricyclic antidepressant overdose".

Authors:  Hossein Sanaei-Zadeh
Journal:  Psychiatry Investig       Date:  2012-01-18       Impact factor: 2.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.